Industries > Pharma > Apixaban Market Report to 2031
Apixaban Market Report to 2031
By Dosage Form (Capsule, Tablet), by End User (Hospitals, Retail Pharmacies, Online Pharmacies, Others). Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
Global Apixaban Market– our new study reveals trends, R&D progress, and predicted revenues
Where is the Global Apixaban Market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our Global Apixaban Market report provides tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Global Apixaban Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.
Apixaban Market by Dosage Form
• Capsule
• Tablet
Apixaban Market by End User
• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Japan
o Rest of Asia Pacific
• Latin America
o Rest of Latin America
• Middle East and Africa
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Apixaban Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Apixaban Market with forecasts for By Dosage Form, By End User each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments.
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Apixaban Market report helps you
In summary, our 280+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Apixaban Market, with forecasts By Dosage Form, By End User each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2031 for 5 regional and 20 key national markets – See forecasts for the Global Apixaban Market in North America, Europe, Asia-Pacific, and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, Rest of Asia Pacific, Latin America and Middle East and Africa, among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for Apixaban of the major companies involved in the Apixaban Market. Some of the company’s profiled in this report include-
• Pfizer, Inc.
• Bristol-Myers Squibb Company
• Aspen Holdings
• Abbott India Laboratories
• Bayer Healthcare AG
• Boehringer Ingelheim
• GlaxoSmithKline Plc.
• Metrochem API Pvt Ltd
• F. Hoffmann-La Roche Ltd
• Portola Pharmaceuticals, Inc.
• Siemens Healthcare GmbH
• Eisai Co. Ltd
• Sanofi S.A
• Otsuka Pharmaceutical
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
With Information found nowhere else
Our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the global Apixaban Market and leading companies. You will find data, trends, and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Apixaban Market Report to 2031: By Dosage Form (Capsule, Tablet), by End User (Hospitals, Retail Pharmacies, Online Pharmacies, Others). Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Global Apixaban Market
2.1. Global Apixaban Market Definition
2.2. By Dosage Form Submarkets Definitions
2.3. By End User Submarkets Definitions
3. Global Apixaban Market Overview
3.1. Global Apixaban Market Size and Forecast by Region
3.2. Global Apixaban Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rising Prevalence of Venous Thromboembolism Events.
3.3.1.2. Cost-Effective Alternative to Warfarin.
3.3.1.3. Increasing Recommendation Among Non-Valvular Atrial Fibrillation Patients to Reduce Risk of Stroke or Systemic Embolism
3.3.2. Market Restraints/Challenges
3.3.2.1. Rising Risk Associated with Bleeding, Which May Be Serious and Potentially Fatal.
3.3.2.2. The Premature Discontinuation of Apixaban Leads to Risk of Thrombotic Events.
3.3.3. Opportunities
3.3.3.1. Government and Private Organizations are Significantly Investing In R&D.
3.3.3.2. FDA Approval of Apixaban Drugs for Clinical Purpose.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Apixaban Market Analysis and Forecast 2021-2031, By Dosage Form (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.2. Capsule
4.2.1.1. The premature discontinuation of oral apixaban (Eliques) leads to high risk of thrombotic events.
4.3. Tablet
4.3.1.1. The US FDA approved generics of Eliquis (apixaban) tablets to reduce the risk of stroke and systemic embolism.
5. Global Apixaban Market Analysis and Forecast, 2021-2031 By End User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Hospitals
5.1.1.1. Increasing admission in hospitals among patients for bleeding events.
5.1.2. Retail Pharmacies
5.1.2.1. Increasing demand for anticoagulants and easy access from retail pharmacies.
5.1.3. Online Pharmacies
5.1.3.1. Pandemic boosts the demand for online pharmacies.
5.1.4. Others
6. North America Apixaban Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.2. North America Apixaban Market Size and Forecast By Dosage Form
6.3. North America Apixaban Market Size and Forecast By End User
6.4. U.S. Apixaban Market
6.4.1. Approval of eliquis by FDA to treat deep vein thrombosis (DVT) prophylaxis and pulmonary embolism (PE).
6.5. Canada Apixaban Market
6.5.1. Increasing hip and knee replacements surgeries in the region.
7. Europe Apixaban Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. Europe Apixaban Market Size and Forecast By Dosage Form
7.3. Europe Apixaban Market Size and Forecast By End User
7.4. UK Apixaban Market
7.4.1. Licensed to Use Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Oral Anticoagulants in the Region
7.5. Germany Apixaban Market
7.5.1. The Knee Replacement Is Much Higher in The Region and Boost the Demand for Apixaban Drugs.
7.6. France Apixaban Market
7.6.1. Increasing Need for Stroke Prevention in Patients with Atrial Fibrillation in the Region.
7.7. Rest of Europe Apixaban Market
8. Asia Pacific Apixaban Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Asia Pacific Apixaban Market Size and Forecast By Dosage Form
8.3. Asia Pacific Apixaban Market Size and Forecast By End User
8.4. China Apixaban Market
8.5. India Apixaban Market
8.5.1. Increasing prescription to reduce strokes & systemic embolism in patients with nonvalvular atrial fibrillation.
8.6. Japan Apixaban Market
8.6.1. Apixaban is significantly cost-effective against warfarin in the region.
8.7. Rest of Asia Pacific Apixaban Market
9. Latin America Apixaban Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Latin America Apixaban Market Size and Forecast By Dosage Form
9.3. Latin America Apixaban Market Size and Forecast By End User
9.3.1. Brazil Apixaban Market
9.3.1.1. Approval of apixaban in the region for clinical use.
9.3.2. Mexico Apixaban Market
9.3.2.1. Patients with VTE who are being given apixaban for the treatment of DVT and PE.
9.3.3. Rest of Latin America Apixaban Market
10. MEA Apixaban Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. MEA Apixaban Market Size and Forecast By Dosage Form
10.3. MEA Apixaban Market Size and Forecast By End User
10.4. South Africa Apixaban Market
10.4.1.1. Cost effective alternative among anticoagulants.
10.5. Rest of MEA Apixaban Market
10.5.1.1. Rising ischemic stroke, systemic embolism, and myocardial infarction.
11. Companies in the Apixaban Market
11.1. Pfizer, Inc
11.1.1. Company Snapshot
11.1.2. Company Overview
11.1.2.1. Net Revenue
11.1.3. Product Offerings
11.1.4. Recent Initiatives (2017-2020)
11.2. Bristol-Myers Squibb Company
11.2.1. Company Snapshot
11.2.2. Company Overview
11.2.3. Financial Performance (2015-2020)
11.2.3.1. Net Revenue
11.2.3.2. Gross Profit
11.2.4. Product Offerings
11.2.5. Recent Initiatives (2017-2020)
11.3. Aspen Holdings
11.3.1. Company Snapshot
11.3.2. Company Overview
11.3.3. Financial Performance (2015-2020)
11.3.3.1. Net Revenue
11.3.3.2. Gross Profit
11.3.4. Product Offerings
11.3.5. Recent Initiatives (2017-2020)
11.4. Abbott India Laboratories
11.4.1. Company Snapshot
11.4.2. Company Overview
11.4.3. Financial Performance (2015-2020)
11.4.3.1. Net Revenue
11.4.4. Product Offerings
11.4.5. Recent Initiatives (2017-2020)
11.5. Bayer Healthcare AG
11.5.1. Company Snapshot
11.5.2. Company Overview
11.5.3. Financial Performance (2015-2020)
11.5.3.1. Net Revenue
11.5.4. Product Offerings
11.5.5. Recent Initiatives (2017-2020)
11.6. Boehringer Ingelheim
11.6.1. Company Snapshot
11.6.2. Company Overview
11.6.3. Financial Performance (2015-2020)
11.6.3.1. Net Revenue
11.6.3.2. Geographical Revenue, 2020
11.6.4. Product Offerings
11.6.5. Recent Initiatives (2017-2020)
11.7. GlaxoSmithKline Plc
11.7.1. Company Snapshot
11.7.2. Company Overview
11.7.3. Financial Performance (2015-2020)
11.7.3.1. Net Revenue
11.7.4. Product Offerings
11.7.5. Recent Initiatives (2017-2020)
11.8. Metrochem API Pvt Ltd
11.8.1. Company Snapshot
11.8.2. Company Overview
11.8.3. Financial Performance (2015-2020)
11.8.3.1. Net Revenue
11.8.4. Product Offerings
11.8.5. Recent Initiatives (2017-2020)
11.9. F. Hoffmann-La Roche Ltd
11.9.1. Company Snapshot
11.9.2. Company Overview
11.9.3. Financial Performance (2015-2020)
11.9.3.1. Net Revenue
11.9.4. Product Offerings
11.9.5. Recent Initiatives (2017-2020)
11.10. Portola Pharmaceuticals, Inc.
11.10.1. Company Snapshot
11.10.2. Company Overview
11.10.3. Financial Performance (2015-2020)
11.10.3.1. Net Revenue
11.10.3.2. Gross Profit
11.10.4. Product Offerings
11.10.5. Recent Initiatives (2017-2020)
11.11. Other Notable Players
12. Conclusion
13. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Apixaban Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Apixaban Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Apixaban Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Apixaban Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Apixaban Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Apixaban Market Drivers & Restraints 2021
Table 7. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Capsule Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Capsule Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Capsule Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Capsule Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Capsule Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Tablet Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Tablet Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Tablet Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Tablet Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Tablet Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Apixaban Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Apixaban Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Apixaban Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Apixaban Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Apixaban Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Regional Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 48. Regional Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Regional Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Regional Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Regional Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 52. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 53. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 54. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 55. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 56. North America Apixaban Market Forecast by Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 57. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 58. North America Apixaban Market Forecast By End User 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 59. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 60. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 61. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 62. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 63. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 64. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 65. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 66. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 67. US Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 68. US Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 69. US Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 70. US Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 71. US Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 73. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 76. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 78. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table81. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Europe Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 83. Europe Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Europe Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Europe Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Europe Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 88. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 92. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 93. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 94. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 95. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 96. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 98. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 102. France Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103. France Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104. France Apixaban Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario U)
Table 105. France Apixaban Market Forecast 2021-2031 (US$M, AGR %CAGR %),(COVID - Scenario W)
Table 106 France Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 111. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Asia Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. Asia Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Asia Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Asia Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Asia Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Asia Pacific Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. Asia Pacific Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Asia Pacific Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Asia Pacific Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Asia Pacific Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 122. Asia Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. Asia Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Asia Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Asia Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Asia Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127 China Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. China Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. China Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. China Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. China Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132 India Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. India Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. India Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. India Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. India Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. RoAPAC Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. RoAPAC Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. RoAPAC Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. RoAPAC Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. RoAPAC Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150 Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152 Middle East Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153 Middle East Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Middle East Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155 Middle East Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Middle East Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164 Latin America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167 Leading 10 Apixaban Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 168. Pfizer Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 169. Pfizer Inc Apixaban Selected Recent Contracts 2020 (Date, Programme Dosage Form, Details)
Table 170. Pfizer, Inc. Apixaban Product Offering (Segment, Product Offerings)
Table 171. Bristol-Myers Squibb Company Profile 2020 (CEO, HQ, Founded, Website)
Table 172. Bristol-Myers Squibb Company Apixaban Product Offering (Segment, Product Offerings)
Table 173. Aspen Holdings Profile 2020 (CEO, HQ, Founded, Website)
Table 174. Aspen Holdings Apixaban Selected Recent Contracts 2017-2020 (Date, Programme Dosage Form, Details)
Table 175. Aspen Holdings Apixaban Product Offering (Segment, Product Offerings)
Table 176. Abbott Laboratories Profile 2020 (CEO, HQ, Founded, Website)
Table 177. Abbott Laboratories Selected Recent Contracts 2015-2020 (Date, Programme Dosage Form, Details)
Table 178. Abbott Laboratories Apixaban Product Offering (Segment, Product Offerings)
Table 179. Bayer Healthcare AG Profile 2020 (CEO, HQ, Founded, Website)
Table 180. Bayer Healthcare AG Apixaban Product Offering (Segment, Product Offerings)
Table 181. Boehringer Ingelheim Profile 2020 (CEO, HQ, Founded, Website)
Table 182. Boehringer Ingelheim Apixaban Selected Recent Contracts 2015-2020 (Date, Programme Dosage Form, Details)
Table 183 Boehringer Ingelheim Apixaban Product Offering (Segment, Product Offerings)
Table 184. GlaxoSmithKline Plc Profile 2020 (CEO, HQ, Founded, Website)
Table 185. GlaxoSmithKline Plc Apixaban Product Offering (Segment, Product Offerings)
Table 186. Metrochem API Pvt Ltd Profile 2020 (CEO, HQ, Founded, Website)
Table 187. Metrochem API Pvt Ltd Apixaban Product Offering (Segment, Product Offerings)
Table 188. F. Hoffmann-La Roche Ltd Profile 2020 (CEO, HQ, Founded, Website)
Table 189. F. Hoffmann-La Roche Ltd Apixaban Product Offering (Segment, Product Offerings)
Table 190. F. Hoffmann-La Roche Ltd Profile 2020 (CEO, Total Company Sales US$M, HQ, Founded, No. of Employees, Ticker, Website)
Table 191. Portola Pharmaceuticals, Inc Total Company Sales 2015-2020 (US$M, AGR %)
Table 192. Portola Pharmaceuticals, Inc Product Offering (Segment, Product Offerings)
Table 193. Other Companies Involved in the Apixaban Market (Company, Location)
LIST OF FIGURES
Figure 1. Apixaban Market Dosage Form Overview
Figure 2. Apixaban Market By Dosage Form Overview
Figure 3. Apixaban Market by End User Overview
Figure 4 Apixaban Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 5. Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 6. Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 7. Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 8. Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 9. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 10. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 11. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 12. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 13. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 14. Apixaban Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 15. Apixaban Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 16. Apixaban Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 17. Apixaban Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 18. Apixaban Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 19. Regional Apixaban Market Forecast 2021-2031 (Sales US$M, Global AGR %)
Figure 20. Regional Apixaban Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure21. Regional Apixaban Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 22. Regional Apixaban Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 23. Regional Apixaban Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 24. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %) (Before COVID)
Figure 25. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 26. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 27. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 28. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 29. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %)
Figure 30. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 31. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 32. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 33. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 34. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 35. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 36. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 37. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 38. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 39. US Apixaban Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 40. US Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 41. US Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 42. US Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 43. US Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 44. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %)
Figure 45. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 46. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 47. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 48. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 49. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M)
Figure 50. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario V)
Figure 51. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario U)
Figure 52. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario W)
Figure 53. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario L)
Figure 54. Europe Apixaban Market Forecast By End User 2021-2031 (US$M) (Before COVID)
Figure 55. Europe Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 56. Europe Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 57. Europe Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 58. Europe Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 59. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 60. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 61. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 62. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 63. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 64. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 65. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 66. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 67. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 68. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 69. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %)
Figure 70. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 71. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 72. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 73. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 74. France Apixaban Market Forecast 2021-2031 (US$M, AGR %)
Figure 75. France Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 76. France Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 77. France Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 78. France Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 79. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 80. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure81. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 82. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 83. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 84 Asia-Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (Before COVID)
Figure 85. Asia-Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario V)
Figure 86. Asia-Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario U)
Figure 87. Asia-Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario W)
Figure 88. Asia-Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario L)
Figure 89. Asia-Pacific Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 90. Asia-Pacific Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 91. Asia-Pacific Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 92. Asia-Pacific Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 93. Asia-Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 94. Asia-Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 95. Asia-Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 96. Asia-Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 97. Asia-Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 98. China Apixaban Market Forecast 2021-2031 (US$M, AGR %)
Figure 99. China Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 100. China Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 101. China Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 102. China Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 103. India Apixaban Market Forecast 2021-2031 (US$M, AGR %)
Figure 104. India Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 105. India Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 106. India Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 107. India Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 108. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 109. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 110. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 111. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 112. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 113. Rest of APAC Apixaban Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 114. Rest of APAC Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 115 Rest of APAC Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 116. Rest of APAC Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 117. Rest of APAC Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 118. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M)
Figure 119. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario V)
Figure 120. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario U)
Figure 121. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario W)
Figure 122. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario L)
Figure 123. Middle East Apixaban Market Forecast By End User 2021-2031 (US$M)
Figure 124. Middle East Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 125. Middle East Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 126. Middle East Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 127. Middle East Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 128. Rest of Middle East Apixaban Market Forecast 2021-2031 (US$M, AGR %)
Figure 129. Rest of Middle East Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 130. Rest of Middle East Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 131. Rest of Middle East Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 132. Rest of Middle East Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 133. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M)
Figure 134. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario V)
Figure 135. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario U)
Figure 136. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario W)
Figure 137. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario L)
Figure 138. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M)
Figure 139. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 140. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 141. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 142. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 143. Rest of Latin America Apixaban Market Forecast 2021-2031 (US$M, AGR %)
Figure 144. Rest of Latin America Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 145. Rest of Latin America Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 146. Rest of Latin America Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 147. Rest of Latin America Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 148. Porter’s Five Force Analysis
Companies Mentioned
1. Pfizer, Inc.
2. Bristol-Myers Squibb Company
3. Aspen Holdings
4. Abbott Laboratories
5. Bayer Healthcare AG
6. Boehringer Ingelheim
7. GlaxoSmithKline Plc.
8. Metrochem API Pvt Ltd
9. F. Hoffmann-La Roche Ltd
10. Portola Pharmaceuticals, Inc.
11. Siemens Healthcare GmbH
12. Eisai Co. Ltd
13. Sanofi S.A
14. Otsuka Pharmaceutical
15. CoaguSense
16. Genentech Inc
17. AstraZeneca plc
18. Eli Lilly and Company
19. Merck & Co., Inc.
20. Lunac Therapeutics
21. Daiichi Sankyo Company Limited
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Global Apixaban Market
2.1. Global Apixaban Market Definition
2.2. By Dosage Form Submarkets Definitions
2.3. By End User Submarkets Definitions
3. Global Apixaban Market Overview
3.1. Global Apixaban Market Size and Forecast by Region
3.2. Global Apixaban Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rising Prevalence of Venous Thromboembolism Events.
3.3.1.2. Cost-Effective Alternative to Warfarin.
3.3.1.3. Increasing Recommendation Among Non-Valvular Atrial Fibrillation Patients to Reduce Risk of Stroke or Systemic Embolism
3.3.2. Market Restraints/Challenges
3.3.2.1. Rising Risk Associated with Bleeding, Which May Be Serious and Potentially Fatal.
3.3.2.2. The Premature Discontinuation of Apixaban Leads to Risk of Thrombotic Events.
3.3.3. Opportunities
3.3.3.1. Government and Private Organizations are Significantly Investing In R&D.
3.3.3.2. FDA Approval of Apixaban Drugs for Clinical Purpose.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Apixaban Market Analysis and Forecast 2021-2031, By Dosage Form (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.2. Capsule
4.2.1.1. The premature discontinuation of oral apixaban (Eliques) leads to high risk of thrombotic events.
4.3. Tablet
4.3.1.1. The US FDA approved generics of Eliquis (apixaban) tablets to reduce the risk of stroke and systemic embolism.
5. Global Apixaban Market Analysis and Forecast, 2021-2031 By End User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Hospitals
5.1.1.1. Increasing admission in hospitals among patients for bleeding events.
5.1.2. Retail Pharmacies
5.1.2.1. Increasing demand for anticoagulants and easy access from retail pharmacies.
5.1.3. Online Pharmacies
5.1.3.1. Pandemic boosts the demand for online pharmacies.
5.1.4. Others
6. North America Apixaban Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.2. North America Apixaban Market Size and Forecast By Dosage Form
6.3. North America Apixaban Market Size and Forecast By End User
6.4. U.S. Apixaban Market
6.4.1. Approval of eliquis by FDA to treat deep vein thrombosis (DVT) prophylaxis and pulmonary embolism (PE).
6.5. Canada Apixaban Market
6.5.1. Increasing hip and knee replacements surgeries in the region.
7. Europe Apixaban Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. Europe Apixaban Market Size and Forecast By Dosage Form
7.3. Europe Apixaban Market Size and Forecast By End User
7.4. UK Apixaban Market
7.4.1. Licensed to Use Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Oral Anticoagulants in the Region
7.5. Germany Apixaban Market
7.5.1. The Knee Replacement Is Much Higher in The Region and Boost the Demand for Apixaban Drugs.
7.6. France Apixaban Market
7.6.1. Increasing Need for Stroke Prevention in Patients with Atrial Fibrillation in the Region.
7.7. Rest of Europe Apixaban Market
8. Asia Pacific Apixaban Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Asia Pacific Apixaban Market Size and Forecast By Dosage Form
8.3. Asia Pacific Apixaban Market Size and Forecast By End User
8.4. China Apixaban Market
8.5. India Apixaban Market
8.5.1. Increasing prescription to reduce strokes & systemic embolism in patients with nonvalvular atrial fibrillation.
8.6. Japan Apixaban Market
8.6.1. Apixaban is significantly cost-effective against warfarin in the region.
8.7. Rest of Asia Pacific Apixaban Market
9. Latin America Apixaban Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Latin America Apixaban Market Size and Forecast By Dosage Form
9.3. Latin America Apixaban Market Size and Forecast By End User
9.3.1. Brazil Apixaban Market
9.3.1.1. Approval of apixaban in the region for clinical use.
9.3.2. Mexico Apixaban Market
9.3.2.1. Patients with VTE who are being given apixaban for the treatment of DVT and PE.
9.3.3. Rest of Latin America Apixaban Market
10. MEA Apixaban Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. MEA Apixaban Market Size and Forecast By Dosage Form
10.3. MEA Apixaban Market Size and Forecast By End User
10.4. South Africa Apixaban Market
10.4.1.1. Cost effective alternative among anticoagulants.
10.5. Rest of MEA Apixaban Market
10.5.1.1. Rising ischemic stroke, systemic embolism, and myocardial infarction.
11. Companies in the Apixaban Market
11.1. Pfizer, Inc
11.1.1. Company Snapshot
11.1.2. Company Overview
11.1.2.1. Net Revenue
11.1.3. Product Offerings
11.1.4. Recent Initiatives (2017-2020)
11.2. Bristol-Myers Squibb Company
11.2.1. Company Snapshot
11.2.2. Company Overview
11.2.3. Financial Performance (2015-2020)
11.2.3.1. Net Revenue
11.2.3.2. Gross Profit
11.2.4. Product Offerings
11.2.5. Recent Initiatives (2017-2020)
11.3. Aspen Holdings
11.3.1. Company Snapshot
11.3.2. Company Overview
11.3.3. Financial Performance (2015-2020)
11.3.3.1. Net Revenue
11.3.3.2. Gross Profit
11.3.4. Product Offerings
11.3.5. Recent Initiatives (2017-2020)
11.4. Abbott India Laboratories
11.4.1. Company Snapshot
11.4.2. Company Overview
11.4.3. Financial Performance (2015-2020)
11.4.3.1. Net Revenue
11.4.4. Product Offerings
11.4.5. Recent Initiatives (2017-2020)
11.5. Bayer Healthcare AG
11.5.1. Company Snapshot
11.5.2. Company Overview
11.5.3. Financial Performance (2015-2020)
11.5.3.1. Net Revenue
11.5.4. Product Offerings
11.5.5. Recent Initiatives (2017-2020)
11.6. Boehringer Ingelheim
11.6.1. Company Snapshot
11.6.2. Company Overview
11.6.3. Financial Performance (2015-2020)
11.6.3.1. Net Revenue
11.6.3.2. Geographical Revenue, 2020
11.6.4. Product Offerings
11.6.5. Recent Initiatives (2017-2020)
11.7. GlaxoSmithKline Plc
11.7.1. Company Snapshot
11.7.2. Company Overview
11.7.3. Financial Performance (2015-2020)
11.7.3.1. Net Revenue
11.7.4. Product Offerings
11.7.5. Recent Initiatives (2017-2020)
11.8. Metrochem API Pvt Ltd
11.8.1. Company Snapshot
11.8.2. Company Overview
11.8.3. Financial Performance (2015-2020)
11.8.3.1. Net Revenue
11.8.4. Product Offerings
11.8.5. Recent Initiatives (2017-2020)
11.9. F. Hoffmann-La Roche Ltd
11.9.1. Company Snapshot
11.9.2. Company Overview
11.9.3. Financial Performance (2015-2020)
11.9.3.1. Net Revenue
11.9.4. Product Offerings
11.9.5. Recent Initiatives (2017-2020)
11.10. Portola Pharmaceuticals, Inc.
11.10.1. Company Snapshot
11.10.2. Company Overview
11.10.3. Financial Performance (2015-2020)
11.10.3.1. Net Revenue
11.10.3.2. Gross Profit
11.10.4. Product Offerings
11.10.5. Recent Initiatives (2017-2020)
11.11. Other Notable Players
12. Conclusion
13. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Apixaban Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Apixaban Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Apixaban Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Apixaban Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Apixaban Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Apixaban Market Drivers & Restraints 2021
Table 7. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Capsule Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Capsule Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Capsule Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Capsule Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Capsule Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Tablet Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Tablet Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Tablet Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Tablet Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Tablet Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Apixaban Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Apixaban Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Apixaban Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Apixaban Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Apixaban Market Forecast By End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Retail Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Regional Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 48. Regional Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Regional Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Regional Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Regional Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 52. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 53. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 54. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 55. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 56. North America Apixaban Market Forecast by Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 57. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 58. North America Apixaban Market Forecast By End User 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 59. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 60. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 61. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 62. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 63. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 64. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 65. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 66. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 67. US Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 68. US Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 69. US Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 70. US Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 71. US Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 73. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 76. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 78. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table81. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Europe Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 83. Europe Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Europe Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Europe Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Europe Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 88. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 92. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 93. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 94. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 95. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 96. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 98. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 102. France Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103. France Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104. France Apixaban Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario U)
Table 105. France Apixaban Market Forecast 2021-2031 (US$M, AGR %CAGR %),(COVID - Scenario W)
Table 106 France Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 111. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Asia Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. Asia Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Asia Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Asia Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Asia Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Asia Pacific Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. Asia Pacific Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Asia Pacific Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Asia Pacific Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Asia Pacific Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 122. Asia Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. Asia Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Asia Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Asia Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Asia Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127 China Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. China Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. China Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. China Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. China Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132 India Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. India Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. India Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. India Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. India Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. RoAPAC Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. RoAPAC Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. RoAPAC Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. RoAPAC Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. RoAPAC Apixaban Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150 Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152 Middle East Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153 Middle East Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Middle East Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155 Middle East Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Middle East Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164 Latin America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167 Leading 10 Apixaban Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 168. Pfizer Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 169. Pfizer Inc Apixaban Selected Recent Contracts 2020 (Date, Programme Dosage Form, Details)
Table 170. Pfizer, Inc. Apixaban Product Offering (Segment, Product Offerings)
Table 171. Bristol-Myers Squibb Company Profile 2020 (CEO, HQ, Founded, Website)
Table 172. Bristol-Myers Squibb Company Apixaban Product Offering (Segment, Product Offerings)
Table 173. Aspen Holdings Profile 2020 (CEO, HQ, Founded, Website)
Table 174. Aspen Holdings Apixaban Selected Recent Contracts 2017-2020 (Date, Programme Dosage Form, Details)
Table 175. Aspen Holdings Apixaban Product Offering (Segment, Product Offerings)
Table 176. Abbott Laboratories Profile 2020 (CEO, HQ, Founded, Website)
Table 177. Abbott Laboratories Selected Recent Contracts 2015-2020 (Date, Programme Dosage Form, Details)
Table 178. Abbott Laboratories Apixaban Product Offering (Segment, Product Offerings)
Table 179. Bayer Healthcare AG Profile 2020 (CEO, HQ, Founded, Website)
Table 180. Bayer Healthcare AG Apixaban Product Offering (Segment, Product Offerings)
Table 181. Boehringer Ingelheim Profile 2020 (CEO, HQ, Founded, Website)
Table 182. Boehringer Ingelheim Apixaban Selected Recent Contracts 2015-2020 (Date, Programme Dosage Form, Details)
Table 183 Boehringer Ingelheim Apixaban Product Offering (Segment, Product Offerings)
Table 184. GlaxoSmithKline Plc Profile 2020 (CEO, HQ, Founded, Website)
Table 185. GlaxoSmithKline Plc Apixaban Product Offering (Segment, Product Offerings)
Table 186. Metrochem API Pvt Ltd Profile 2020 (CEO, HQ, Founded, Website)
Table 187. Metrochem API Pvt Ltd Apixaban Product Offering (Segment, Product Offerings)
Table 188. F. Hoffmann-La Roche Ltd Profile 2020 (CEO, HQ, Founded, Website)
Table 189. F. Hoffmann-La Roche Ltd Apixaban Product Offering (Segment, Product Offerings)
Table 190. F. Hoffmann-La Roche Ltd Profile 2020 (CEO, Total Company Sales US$M, HQ, Founded, No. of Employees, Ticker, Website)
Table 191. Portola Pharmaceuticals, Inc Total Company Sales 2015-2020 (US$M, AGR %)
Table 192. Portola Pharmaceuticals, Inc Product Offering (Segment, Product Offerings)
Table 193. Other Companies Involved in the Apixaban Market (Company, Location)
LIST OF FIGURES
Figure 1. Apixaban Market Dosage Form Overview
Figure 2. Apixaban Market By Dosage Form Overview
Figure 3. Apixaban Market by End User Overview
Figure 4 Apixaban Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 5. Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 6. Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 7. Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 8. Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 9. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 10. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 11. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 12. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 13. Apixaban Submarket Forecast By Dosage Form 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 14. Apixaban Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 15. Apixaban Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 16. Apixaban Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 17. Apixaban Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 18. Apixaban Submarket Forecast By End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 19. Regional Apixaban Market Forecast 2021-2031 (Sales US$M, Global AGR %)
Figure 20. Regional Apixaban Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure21. Regional Apixaban Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 22. Regional Apixaban Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 23. Regional Apixaban Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 24. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %) (Before COVID)
Figure 25. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 26. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 27. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 28. North America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 29. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %)
Figure 30. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 31. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 32. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 33. North America Apixaban Market Forecast By End User 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 34. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 35. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 36. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 37. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 38. North America Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 39. US Apixaban Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 40. US Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 41. US Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 42. US Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 43. US Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 44. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %)
Figure 45. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 46. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 47. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 48. Canada Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 49. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M)
Figure 50. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario V)
Figure 51. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario U)
Figure 52. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario W)
Figure 53. Europe Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario L)
Figure 54. Europe Apixaban Market Forecast By End User 2021-2031 (US$M) (Before COVID)
Figure 55. Europe Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 56. Europe Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 57. Europe Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 58. Europe Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 59. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 60. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 61. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 62. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 63. Europe Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 64. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 65. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 66. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 67. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 68. UK Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 69. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %)
Figure 70. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 71. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 72. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 73. Germany Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 74. France Apixaban Market Forecast 2021-2031 (US$M, AGR %)
Figure 75. France Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 76. France Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 77. France Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 78. France Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 79. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 80. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure81. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 82. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 83. Rest of Europe Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 84 Asia-Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (Before COVID)
Figure 85. Asia-Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario V)
Figure 86. Asia-Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario U)
Figure 87. Asia-Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario W)
Figure 88. Asia-Pacific Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario L)
Figure 89. Asia-Pacific Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 90. Asia-Pacific Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 91. Asia-Pacific Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 92. Asia-Pacific Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 93. Asia-Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 94. Asia-Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 95. Asia-Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 96. Asia-Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 97. Asia-Pacific Apixaban Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 98. China Apixaban Market Forecast 2021-2031 (US$M, AGR %)
Figure 99. China Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 100. China Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 101. China Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 102. China Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 103. India Apixaban Market Forecast 2021-2031 (US$M, AGR %)
Figure 104. India Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 105. India Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 106. India Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 107. India Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 108. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 109. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 110. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 111. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 112. Japan Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 113. Rest of APAC Apixaban Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 114. Rest of APAC Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 115 Rest of APAC Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 116. Rest of APAC Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 117. Rest of APAC Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 118. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M)
Figure 119. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario V)
Figure 120. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario U)
Figure 121. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario W)
Figure 122. Middle East Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario L)
Figure 123. Middle East Apixaban Market Forecast By End User 2021-2031 (US$M)
Figure 124. Middle East Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 125. Middle East Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 126. Middle East Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 127. Middle East Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 128. Rest of Middle East Apixaban Market Forecast 2021-2031 (US$M, AGR %)
Figure 129. Rest of Middle East Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 130. Rest of Middle East Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 131. Rest of Middle East Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 132. Rest of Middle East Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 133. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M)
Figure 134. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario V)
Figure 135. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario U)
Figure 136. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario W)
Figure 137. Latin America Apixaban Market Forecast By Dosage Form 2021-2031 (US$M) (COVID - Scenario L)
Figure 138. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M)
Figure 139. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 140. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 141. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 142. Latin America Apixaban Market Forecast By End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 143. Rest of Latin America Apixaban Market Forecast 2021-2031 (US$M, AGR %)
Figure 144. Rest of Latin America Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 145. Rest of Latin America Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 146. Rest of Latin America Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 147. Rest of Latin America Apixaban Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 148. Porter’s Five Force Analysis
Companies Mentioned
1. Pfizer, Inc.
2. Bristol-Myers Squibb Company
3. Aspen Holdings
4. Abbott Laboratories
5. Bayer Healthcare AG
6. Boehringer Ingelheim
7. GlaxoSmithKline Plc.
8. Metrochem API Pvt Ltd
9. F. Hoffmann-La Roche Ltd
10. Portola Pharmaceuticals, Inc.
11. Siemens Healthcare GmbH
12. Eisai Co. Ltd
13. Sanofi S.A
14. Otsuka Pharmaceutical
15. CoaguSense
16. Genentech Inc
17. AstraZeneca plc
18. Eli Lilly and Company
19. Merck & Co., Inc.
20. Lunac Therapeutics
21. Daiichi Sankyo Company Limited
Companies Profiled in the Report
1. Pfizer, Inc.
2. Bristol-Myers Squibb Company
3. Aspen Holdings
4. Abbott India Laboratories
5. Bayer Healthcare AG
6. Boehringer Ingelheim
7. GlaxoSmithKline Plc.
8. Metrochem API Pvt Ltd
9. F. Hoffmann-La Roche Ltd
10. Portola Pharmaceuticals, Inc.
11. Siemens Healthcare GmbH
12. Eisai Co. Ltd
13. Sanofi S.A
14. Otsuka Pharmaceutical
List of Companies Mentioned in the Report:
1. Pfizer, Inc.
2. Bristol-Myers Squibb Company
3. Aspen Holdings
4. Abbott India Laboratories
5. Bayer Healthcare AG
6. Boehringer Ingelheim
7. GlaxoSmithKline Plc.
8. Metrochem API Pvt Ltd
9. F. Hoffmann-La Roche Ltd
10. Portola Pharmaceuticals, Inc.
11. Siemens Healthcare GmbH
12. Eisai Co. Ltd
13. Sanofi S.A
14. Otsuka Pharmaceutical
15. CoaguSense, Inc.
16. Genentech Inc
17. AstraZeneca plc
18. Eli Lilly and Company
19. Merck & Co., Inc.
20. Lunac Therapeutics
21. Daiichi Sankyo Company Limited
List of Organizations Mentioned in the Report
1. World Health Organization
2. American College of Cardiology
3. National Center for Biotechnology Information
4. National Institute for Health and Care Excellence
5. European Association of Hospital Pharmacy
6. The International Society on Thrombosis and Haemostasis
7. American Heart Association
8. International Society of Blood Transfusion.
9. Stanford Healthcare
10. Epidemic Analysis Dashboard
11. American University Radio
12. Massachusetts Medical Society.
13. The European Medicines Agency (EMA)
14. US Food & Drug Administration
15. US National Library of Medicine
16. National Institutes of Health
17. The Biomedical Advanced Research and Development Authority (BARDA)
18. National Organisation for Rare Diseases
19. National Association for Biomedical Research
20. Center for Disease Control and Prevention CDC
21. Journal of the American college of Cardiology
22. Center for Diseases Dynamics, Economics & Policy (CDDEP)
23. The Global Health Security Agenda (GHSA)
24. American Society of Microbiology
25. National Institute on Drug Abuse
26. The United Nations Office on Drugs and Crime (UNODC)
1. Pfizer, Inc.
2. Bristol-Myers Squibb Company
3. Aspen Holdings
4. Abbott India Laboratories
5. Bayer Healthcare AG
6. Boehringer Ingelheim
7. GlaxoSmithKline Plc.
8. Metrochem API Pvt Ltd
9. F. Hoffmann-La Roche Ltd
10. Portola Pharmaceuticals, Inc.
11. Siemens Healthcare GmbH
12. Eisai Co. Ltd
13. Sanofi S.A
14. Otsuka Pharmaceutical
List of Companies Mentioned in the Report:
1. Pfizer, Inc.
2. Bristol-Myers Squibb Company
3. Aspen Holdings
4. Abbott India Laboratories
5. Bayer Healthcare AG
6. Boehringer Ingelheim
7. GlaxoSmithKline Plc.
8. Metrochem API Pvt Ltd
9. F. Hoffmann-La Roche Ltd
10. Portola Pharmaceuticals, Inc.
11. Siemens Healthcare GmbH
12. Eisai Co. Ltd
13. Sanofi S.A
14. Otsuka Pharmaceutical
15. CoaguSense, Inc.
16. Genentech Inc
17. AstraZeneca plc
18. Eli Lilly and Company
19. Merck & Co., Inc.
20. Lunac Therapeutics
21. Daiichi Sankyo Company Limited
List of Organizations Mentioned in the Report
1. World Health Organization
2. American College of Cardiology
3. National Center for Biotechnology Information
4. National Institute for Health and Care Excellence
5. European Association of Hospital Pharmacy
6. The International Society on Thrombosis and Haemostasis
7. American Heart Association
8. International Society of Blood Transfusion.
9. Stanford Healthcare
10. Epidemic Analysis Dashboard
11. American University Radio
12. Massachusetts Medical Society.
13. The European Medicines Agency (EMA)
14. US Food & Drug Administration
15. US National Library of Medicine
16. National Institutes of Health
17. The Biomedical Advanced Research and Development Authority (BARDA)
18. National Organisation for Rare Diseases
19. National Association for Biomedical Research
20. Center for Disease Control and Prevention CDC
21. Journal of the American college of Cardiology
22. Center for Diseases Dynamics, Economics & Policy (CDDEP)
23. The Global Health Security Agenda (GHSA)
24. American Society of Microbiology
25. National Institute on Drug Abuse
26. The United Nations Office on Drugs and Crime (UNODC)
Download sample pages
Complete the form below to download your free sample pages for Apixaban Market Report to 2031Download sample pages
Complete the form below to download your free sample pages for Apixaban Market Report to 2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033
The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.
20 March 2023
Visiongain Publishes eClinical Solutions Market Report 2023-2033
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
17 March 2023
Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
15 March 2023
Visiongain Publishes Regenerative Medicine Market Report 2023-2033
The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.
10 March 2023
